Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- February 28, 2019 Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
- February 26, 2019 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
- February 12, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- February 11, 2019 Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
- February 5, 2019 Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
- January 31, 2019 Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe
- January 2, 2019 Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
- December 20, 2018 Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy
- December 20, 2018 Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
- December 3, 2018 Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
Displaying 211 - 220 of 260